<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Adam A</submitter><funding>Bill and Melinda Gates Foundation</funding><pagination>4030-4039</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11650653</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>10(12)</volume><pubmed_abstract>The coronavirus pandemic outbreak of 2019 highlighted the critical importance of preparedness for current and future public health threats (https://www.mmv.org/mmv-open/global-health-priority-box/about-global-health-priority-box). While the main attention for the past few years has been on COVID-19 research, this focus has reduced global resources on research in other areas, including malaria and neglected tropical diseases (NTDs). Such a shift in focus puts at risk the hard-earned progress in global health achieved over the past two decades (https://www.who.int/news-room/spotlight/10-global-health-issues-to-track-in-2021). To address the urgent need for new drugs to combat drug-resistant malaria, emerging zoonotic diseases, and vector control, Medicines for Malaria Venture (MMV) and Innov</pubmed_abstract><journal>ACS infectious diseases</journal><pubmed_title>Global Health Priority Box─Proactive Pandemic Preparedness.</pubmed_title><pmcid>PMC11650653</pmcid><funding_grant_id>INV-007155</funding_grant_id><pubmed_authors>Norton L</pubmed_authors><pubmed_authors>Hawryluk N</pubmed_authors><pubmed_authors>Burrows JN</pubmed_authors><pubmed_authors>Hooft van Huisjduijnen R</pubmed_authors><pubmed_authors>Bryant R</pubmed_authors><pubmed_authors>Laleu B</pubmed_authors><pubmed_authors>Adam A</pubmed_authors><pubmed_authors>Besson D</pubmed_authors><pubmed_authors>Willis PA</pubmed_authors><pubmed_authors>Samby KK</pubmed_authors><pubmed_authors>Canan S</pubmed_authors><pubmed_authors>Rees S</pubmed_authors><pubmed_authors>Palmer M</pubmed_authors><pubmed_authors>Robinson D</pubmed_authors></additional><is_claimable>false</is_claimable><name>Global Health Priority Box─Proactive Pandemic Preparedness.</name><description>The coronavirus pandemic outbreak of 2019 highlighted the critical importance of preparedness for current and future public health threats (https://www.mmv.org/mmv-open/global-health-priority-box/about-global-health-priority-box). While the main attention for the past few years has been on COVID-19 research, this focus has reduced global resources on research in other areas, including malaria and neglected tropical diseases (NTDs). Such a shift in focus puts at risk the hard-earned progress in global health achieved over the past two decades (https://www.who.int/news-room/spotlight/10-global-health-issues-to-track-in-2021). To address the urgent need for new drugs to combat drug-resistant malaria, emerging zoonotic diseases, and vector control, Medicines for Malaria Venture (MMV) and Innov</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Dec</publication><modification>2025-04-04T01:08:57.532Z</modification><creation>2025-04-04T01:08:57.532Z</creation></dates><accession>S-EPMC11650653</accession><cross_references><pubmed>39488746</pubmed><doi>10.1021/acsinfecdis.4c00700</doi></cross_references></HashMap>